

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. P32701C2	PREDECESSOR SERIAL NO. 10/320,081 <i>10/666,440</i>
<b>INFORMATION DISCLOSURE STATEMENT</b> <b>BY APPLICANT</b> <i>(Use several sheets if necessary)</i>		APPLICANT Henkel	
		FILING DATE Herewith	GROUP 1615

## U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
------------------	-----------------	------	------	-------	----------	-------------------------------

## FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Subclass	Translation Yes   No
-----------------	------	---------	-------	----------	-------------------------

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>May</i>		38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, USA, poster nos. F90 (Paek et al.), F93 (Kim et al.), F97 (Ridgway et al.), F98 (Moore et al.), F106 (Kelly et al.), Sept. 26, 1998
		European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), March 20-23, 1999, poster no. P221 (Kelly et al.)
		39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, USA, Sept. 26-29, 1999, poster nos. 0537 (C.L. Clark et al.), 1494 (A. Ogasawara et al.), 1498 (L.M. Ednie et al.), 1499 (T.A. Davies et al.), 1548 (V. Berrie et al.), 2312 (P.M. Roblin et al.)
		3rd European Congress of Chemotherapy, Madrid, Spain, May 7-10, 2000, poster nos. M101 (P.C. Appelbaum et al.), M102 (P.C. Appelbaum et al.), M106/7 (C.L. Clark et al.), M118 (D.J. Hoban et al.), M125 (P. Ball et al.), M126 (P. Gehanno et al.), M127 (R.N. Gruneberg et al.), M128 (K. Naber et al.), M129 (T. File et al.), M130 (T.J. Henkel et al.)
		40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, Sept. 17-20, 2000, poster nos. 110 (M. Boles et al.), 812 (R. Wilson et al.), 813 (T.J. Henkel et al.), 815 (R. Wilson et al.), 821 (N. Bird et al.), 1014 (R. Page et al.), 2129 (M. Boles et al.)
		Annual Meeting of the Infectious Diseases Society of America, New Orleans, USA, poster no. 262 (T. File et al.) (2000)
		Ball, P., Epidemiology and treatment of chronic bronchitis and its exacerbations. Chest 1995; 108:43S-52S
		Ball, P., et al., Acute exacerbation of chronic bronchitis: an international comparison. Chest 1998; 113(Suppl.): 199S-204S.
		Chen et al., Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada, N. Engl. J. Med. 1999; 22:233-239
		Cormican, M.G., et al., Antimicrobial activity and spectrum of LB20304, a novel fluoroquinolone. Antimicrob Agents Chemother 1997; 41: 204-211
		Cormican, "Comparative Antimicrobial and Spectrum Activity of LB20304a, a New Fluorinated Naphthyridone Compound", Abstracts of the 36th ICAAC, 109 Abst F53 (1996)
		Davies, T., et al., Antipneumococcal activities of gemifloxacin compared to those of nine other agents. Antimicrob Agents Chemother 2000; 44:304-310
		File, et al., Gemifloxacin versus Amoxicillin/Clavulanate in the treatment of Acute Exacerbations of Chronic Bronchitis, J. Chemotherapy, vol. 12 no. 4 (314-325) 2000
		Grossman, Guidelines for the Treatment of Acute Exacerbations of Chronic Bronchitis, Chest, vol. 112, no. 6, December 1997, suppl.; 310s-313s
<i>✓</i>		Grossman, et al. A 1-Year Community-Based Health Economic Study of Ciprofloxacin vs. Usual Antibiotic Treatment in Acute Exacerbations of Chronic Bronchitis, Chest, vol. 113, no. 1, January 1998; 313-141

EXAMINER

*Michael J. ...*

DATE CONSIDERED

*5/14/04*

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. P32701C2	PREDECESSOR SERIAL NO. 10/320,081 <i>10/666, 440</i>
<b>INFORMATION DISCLOSURE STATEMENT</b> <b>BY APPLICANT</b> <i>(Use several sheets if necessary)</i>		APPLICANT Henkel	
		FILING DATE Herewith	GROUP 1615

## U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
------------------	-----------------	------	------	-------	----------	----------------------------

## FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Subclass	Translation Yes   No
-----------------	------	---------	-------	----------	-------------------------

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>MPY</i>	Gwaltney, J.M., Acute Bronchitis, Mandell et al., Editors, Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases, 4th Ed., pp. 606-608 (1995)
	Heaton, V.J., et al., Activity of gemifloxacin against penicillin and ciprofloxacin resistant Streptococcus pneumoniae displaying topoisomerase and efflux mediated resistance mechanisms. Antimicrob Agents Chemother 1999; 43:2998-3000
	Hohl, A.F., et al., International multicenter investigation of LB20304, a new fluoronaphthyridone. Clin Microbiol Infect 1998; 4: 280-284
	Hong, C.Y., et al., "Novel Fluoroquinolone Antibacterial Agents Containing Oxime-Substituted (Aminomethyl) pyrrolidines: Synthesis and Antibacterial Activity of 7-(4-(Aminomethyl)-3-(methoxyimino) pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro [1,8] naphthyridine-3-carboxylic Acid (LB20304)", J. Med. Chem. 40 (22) pp. 3584-3593 (1997)
	Kim, M., et al, "In Vitro Activities of LB20304, a New Fluoroquinolone", Arch. Pharm. Res. Vol. 19, No. 1, pp. 52-59 (1996)
	Kim, M-Y, et al, "Bacterial Resistance to LB20304, a New Fluoroquinolone Antibiotic, Arch. Pharm. Res. Vol. 19, No. 5, pp. 400-405 (1996)
	Kwak, J-H., "Antimicrobial Activities of LB20304a, a New Quinolone Antibiotic", The Journal of Applied Pharmacology (4) pp. 378-384 (1996)
	Lowe, et al., Gemifloxacin, Drugs, vol. 59, no. 5, pages 1137-1147, May 2000.
	Marco, F., et al., "Antimicrobial Activity of LB20304, a Fluoronaphthyridone, Tested Against Anaerobic Bacteria", J. Antimicrobial Chemother Vol. 40, No. 4, pp. 605-607 (1997)
	Morrissey, G., Purification of pneumococcal type II topoisomerases from S. pneumoniae and inhibition by fluoroquinolones. J. Antimicrob Chemother 2000 45(Suppl. S1): 101-106
	Niederman, et al., Treatment Cost of Acute Exacerbations of Chronic Bronchitis, Clinical Therapeutics, vol. 21, no. 3, pages 576-591, 1999
	Oh, J-L., et al., In vitro and in vivo evaluations of LB20304, a new fluoronaphthyridone. Antimicrob Agents Chemother 1996; 40: 1564-1568
	Pechere, et al., Optimizing economic outcomes in antibiotic therapy of patients with acute bacterial exacerbations of chronic bronchitis, J. of Antimicrobial Chemotherapy, 45, Topic T2, pages 19-24, 2000
	Reynolds, H.Y., Chronic Bronchitis and Acute Infectious Exacerbations, Mandell et al., Editors, Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases, 4th Ed., pp. 608-612 (1995)
	Rittenhouse, S., et al., In vitro antibacterial activity of gemifloxacin and comparator compounds against common respiratory pathogens. J Antimicrob Chemother 2000; 45(Suppl S1): 23-27
	Roblin, P.M., et al., In vitro activity of gemifloxacin (SB-265805, LB20304) against recent isolates of Chlamydia pneumoniae. Antimicrob Agents Chemother 1999; 43:2806-2807
	Wise, R., et al. The in vitro activity and tentative breakpoint of gemifloxacin, a new fluoroquinolone, J. Antimicrob Chemother 1999; 44: 679-688
<i>✓</i>	Zeckel et al., Loracarbef (LY163892) versus amoxicillin/clavulanate in the treatment of acute bacterial exacerbations of chronic bronchitis. Clin Ther 1992; 14:214-229

EXAMINER <i>Michael Paul Young</i>	DATE CONSIDERED <i>8/14/04</i>
---------------------------------------	-----------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.